Program
Brentuximab Vedotin
Also written as “brentuximab vedotin”, “Brentuximab vedotin” and “SGN-35”.
Its studies are mostly in Hodgkin Disease · Lymphoma, Large-Cell, Anaplastic · Lymphoma, Large B-Cell, Diffuse · Lymphoma, T-Cell, Peripheral · Melanoma, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 241 open or running | phase 3since Apr 6, 2010 | Feb 1, 2007 | none ahead |
| Takeda | 113 open or running | phase 4since Jul 1, 2013 | Dec 12, 2011 | Mar 31, 2028phase 4 · NCT06831370 |
| Bristol-Myers Squibb | 20 open or running | phase 3since May 1, 2017 | Oct 13, 2015 | none ahead |
Also a collaborator on its studies: Merck, Takeda Development Center Americas and Ono Pharmaceutical.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 22 studies since Feb 1, 2007.
- Jul 9, 2015Phase 2 study in Lupus Erythematosus, SystemicPfizer · NCT02533570 · 20 enrolled · United States
- Oct 7, 20152 phase 2 studiesPfizer · NCT02572167, NCT02594163
- Oct 13, 2015Bristol-Myers Squibb’s first study: phase 2 study in Non-Hodgkin's DiseaseNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT02581631 · 145 enrolled · United States, Canada, France and more
- Oct 18, 2016Phase 2 study in Hodgkin DiseaseTakeda · NCT02939014 · 39 enrolled · China
- Nov 11, 2016Phase 2 study in Hodgkin DiseaseTakeda · NCT02979522 · 59 enrolled · United States, Brazil, Italy and more
- May 1, 2017Phase 3 study in Hodgkin DiseaseBristol-Myers Squibb · NCT03138499 · 23 enrolled · United States, Japan, Puerto Rico
- May 9, 2019Phase 2 study in Hodgkin DiseasePfizer · NCT03947255 · 12 enrolled · United States
- May 21, 2020Phase 3 study in Lymphoma, Large B-Cell, DiffusePfizer · NCT04404283 · 240 enrolled · United States, Australia, Belgium and more
- Sep 23, 2020Phase 2 study in Lymphoma, T-Cell, PeripheralPfizer · NCT04569032 · 82 enrolled · United States, France, Italy and more
- Oct 23, 2020Phase 2 study in MelanomaPfizer · NCT04609566 · 161 enrolled · United States
- Feb 7, 2022Phase 1 study in Acquired Immunodeficiency SyndromePfizer · NCT05244473 · United States
- Jun 30, 2022Phase 4 study in Lymphoma, T-CellTakeda · NCT05442554 · 10 enrolled · China
- Jan 4, 2023Phase 2 study in LymphomaTakeda · NCT05673785 · 52 enrolled · China
- Feb 14, 2025Phase 4 study in Hodgkin DiseaseTakeda · NCT06831370 · 124 planned · India
Ahead
- Mar 31, 2028Primary completion: phase 4 study in Hodgkin DiseaseTakeda · NCT06831370
TargetBeta
“An antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 ”NCIt, by rule
“Tumor necrosis factor receptor superfamily member 8 binding agent”ChEMBL 37, by rule
Studies
All 37 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06831370Hodgkin Disease · India | 4 | Recruiting | Takeda | Mar 31, 2028 | 124 |
| NCT05673785Lymphoma · China | 2 | Active, not recruiting | Takeda | Apr 27, 2025 | 52 |
| NCT05442554Lymphoma, T-Cell · China | 4 | Completed | Takeda | Aug 9, 2024 | 10 |
| NCT05244473Acquired Immunodeficiency Syndrome · United States | 1 | Withdrawn | Pfizer | May 31, 2024 | 0 |
| NCT04609566Melanoma · United States | 2 | Completed | Pfizer | Feb 3, 2026 | 161 |
| NCT04569032Lymphoma, T-Cell, Peripheral · United States, France, Italy and more | 2 | Completed | Pfizer | May 9, 2024 | 82 |
| NCT04404283Lymphoma, Large B-Cell, Diffuse · United States, Australia, Belgium and more | 3 | Active, not recruiting | Pfizer | Jan 23, 2026 | 240 |
| NCT03947255Hodgkin Disease · United States | 2 | Terminated | Pfizer | Nov 6, 2022 | 12 |
| NCT03138499Hodgkin Disease · United States, Japan, Puerto Rico | 3 | Terminated | Bristol-Myers Squibb | Feb 22, 2021 | 23 |
| NCT02979522Hodgkin Disease · United States, Brazil, Italy and more | 2 | Active, not recruiting | Takeda | May 5, 2020 | 59 |
| NCT02939014Hodgkin Disease · China | 2 | Completed | Takeda | Aug 2, 2018 | 39 |
| NCT02594163Diffuse Large B-cell Lymphoma Refractory · United States, Czechia, France and more | 2 | Terminated | Pfizer | Sep 2017 | 25 |
| NCT02581631Non-Hodgkin's Disease · United States, Canada, France and more | 2 | Completed | Bristol-Myers Squibb | Jan 16, 2020 | 145 |
| NCT02572167Hodgkin Disease · United States | 2 | Completed | Pfizer | Mar 1, 2018 | 93 |
| NCT02533570Lupus Erythematosus, Systemic · United States | 2 | Terminated | Pfizer | Jun 5, 2017 | 20 |
| NCT01990534Hodgkin Disease · Czechia, Germany, Malaysia and more | 4 | Completed | Takeda | Mar 24, 2016 | 60 |
| NCT01950364Hodgkin Disease · Belgium, Lithuania, Spain | 1 | Completed | Takeda | Oct 2014 | 20 |
| NCT01925612Lymphoma, B-Cell · United States, Czechia, Italy and more | 2 | Terminated | Pfizer | May 1, 2017 | 87 |
| NCT01909934Lymphoma · Belgium, Croatia, Czechia and more | 4 | Completed | Takeda | May 4, 2021 | 50 |
| NCT01874054Hodgkin Disease · United States | 2 | Completed | Pfizer | Dec 2015 | 55 |
| NCT01777152Lymphoma, Large-Cell, Anaplastic · United States, Australia, Canada and more | 3 | Completed | Pfizer | Aug 15, 2018 | 452 |
| NCT01712490Hodgkin Disease · United States, Australia, Belgium and more | 3 | Completed | Takeda | Apr 20, 2017 | 1,334 |
| NCT01716806Hodgkin Disease · United States, Canada | 2 | Completed | Pfizer | Apr 7, 2023 | 131 |
| NCT01578499Lymphoma, Primary Cutaneous Anaplastic Large Cell · United States, Australia, Austria and more | 3 | Completed | Takeda | May 31, 2016 | 131 |
| NCT01492088Recurrence · United States, France, Germany and more | 2 | Completed | Takeda | Oct 12, 2016 | 36 |
| NCT01461538Precursor Cell Lymphoblastic Leukemia-Lymphoma · United States | 2 | Completed | Pfizer | Dec 2014 | 84 |
| NCT01421667Lymphoma, B-Cell · United States, Canada | 2 | Completed | Pfizer | Jun 2015 | 176 |
| NCT01309789Lymphoma, Large-Cell, Anaplastic · United States, United Kingdom | 1 | Completed | Pfizer | Apr 2013 | 39 |
| NCT01100502Hodgkin Disease · United States, Bulgaria, Czechia and more | 3 | Completed | Pfizer | Aug 31, 2014 | 329 |
| NCT01060904Hodgkin Disease · United States, Canada | 1 | Completed | Pfizer | Sep 2012 | 51 |
| NCT01026415Carcinoma · United States | 1 | Completed | Pfizer | May 2012 | 73 |
| NCT01026233Hodgkin Disease · United States, Germany | 1 | Completed | Pfizer | Aug 2010 | 52 |
| NCT00947856Hodgkin Disease · United States, France | 2 | Completed | Pfizer | Mar 2013 | 110 |
| NCT00866047Lymphoma, Large-Cell, Anaplastic · United States, Belgium, Canada and more | 2 | Completed | Pfizer | Aug 2010 | 58 |
| NCT00848926Hodgkin Disease · United States, Belgium, Canada and more | 2 | Completed | Pfizer | Aug 2010 | 102 |
| NCT00649584Hodgkin Disease · United States | 1 | Terminated | Pfizer | Feb 2010 | 44 |
| NCT00430846Lymphoma, Non-Hodgkin · United States | 1 | Completed | Pfizer | Jul 2009 | 45 |
How it is read
Names in the registry
- “brentuximab vedotin”, 27 entries
- “Brentuximab vedotin”, 7 entries
- “Brentuximab Vedotin”, 7 entries
- “SGN-35”, 2 entries
- “Brentuximab vedotin and rifampicin”, 1 entry
Conditions, from the studies’ own filings
- Hodgkin Disease, 18 studies
- Lymphoma, Large-Cell, Anaplastic, 5 studies
- Lymphoma, Large B-Cell, Diffuse, 4 studies
- Lymphoma, T-Cell, Peripheral, 1 study
- Melanoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.